... angiotensin II arginine vasopressin atrial natriuretic peptide brain natriuretic peptide cyclic GMP glomerular filtration rate heart failure lithium renal plasma flow renin sodium 5Clinical Science (1999) 96, 5 15 (Printed in Great Britain) Renal effects of brain natriuretic peptide in patients...

... and glomerular sclerosis. 2. We have investigated the urinary excretion of the metabolites of thromboxane (thromboxane B2) and prostacyclin (6-keto prostaglandin F 1α ), and of endothelin and cyclic GMP as markers for changes in the balance of renal haemodynamic factors in the obese Zucker rat. 3. Obese fa/fa...

... by positron emission tomography with H 2 15 O as flow tracer. Plasma l-arginine and cyclic GMP (cGMP) levels were determined at the same time points. 3. l-arginine induced a dose-related decrease in blood pressure during the infusion period. MBF and plasma cGMP levels during and after the infusion of 8 g of l...

... months with low outdoor temperature. The l-arginine—nitric oxide (NO)—cyclic GMP (cGMP) pathway plays an important role in counteracting vasospasm. The aim of the present study was to investigate if the venous cGMP response to whole-body cooling in women with PRP varied with the season of the year. 2...

... and the Medical Research Society 1997 cyclic GMP haemodynamics natriuresis ventricular pacing Clinical Science (1997) 92, 159-165 (Printed in Great Britain) I59 Comparative bioactivity of atrial and brain natriuretic peptides in an ovine model of heart failup \ \ Miriam Tessa RADEMAKER, Christopher...

... inhibition augments endogenous atrial and brain natriuretic peptide. cyclic GMP haemodynamics natriuresis ventricular pacing Clinical Science (1996) 91, 283-291 (Printed i n Great Britain) 283 Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic...

...S. M. Bode-Böger; R. H. Böger; A. Creutzig; D. Tsikas; F.-M. Gutzki; K. Alexander; J. C. Frölich 1. L-Arginine is the physiological precursor of nitric oxide which induces vasodilatation and inhibits platelet aggregation by the formation of cyclic GMP. 2. In the present study we investigated...

... reaction in vitro in non-pregnant, healthy pregnant and pre-eclamptic women; (ii) the concentration of cyclic GMP during incubation of washed platelets with sodium nitroprusside in a separate group of non-pregnant, healthy pregnant and pre-eclamptic women. 3. The half-maximal inhibitory concentration...

..., revealing the presence of β-atrial natriuretic peptide as well as α- and γ-atrial natriuretic peptide. 3. The pericardial fluid concentration of cyclic GMP, the intracellular second messenger for atrial natriuretic peptide, was significantly higher in patients with congestive heart failure than in patients...

...G. A. Sagnella; N. D. Markandu; M. G. Buckley; D. R. J. Singer; G. A. MacGregor 1. The present study was designed to investigate the relationships between circulating atrial natriuretic peptide, plasma and urinary cyclic GMP and sodium excretion under basal conditions and in response to changes...

... ± 3.7 pmol/l and 2.64 ± 0.38%, respectively). Sinorphan inhibited plasma neutral endopeptidase activity by 68–75% 30 min after ingestion. This effect persisted for at least 4 h. There were simultaneously increases in plasma atrial natriuretic factor and cyclic GMP levels to 1.9 and 1.4 times the basal...

...Stephen C. Pang; Minh-Chau Hoang; Johanne Tremblay; Marc Cantin; Raul Garcia; Jacques Genest; Pavel Hamet 1. The differential effects of extracted and synthetic atrial natriuretic factor (ANF) on arterial blood pressure, natriuresis, and cyclic GMP excretion were studied in normotensive (WKY...

... in plasma cyclic GMP concentration, whether or not glucose was infused after the hormone. 4. Glucagon (3–300 nmol, 10–1000 μg), caused a dose-dependent increase in plasma cyclic AMP concentration. The rise in plasma cyclic AMP produced by 3 or 30 nmol of glucagon was not significantly modified...